(Q37037373)

17 August 2017

1 reference

title

Advances in the treatment of breast cancer. (English)

1 reference

17 August 2017

1 reference

Moulder S

1

1 reference

17 August 2017

Hortobagyi GN

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

19 December 2007

1 reference

Clinical Pharmacology & Therapeutics

17 August 2017

published in

1 reference

17 August 2017

volume

83

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

26-36

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100449

17 August 2017

exact match

0 references

cites work

Effect of screening and adjuvant therapy on mortality from breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Neoadjuvant use of endocrine therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

DNA topoisomerase II as a target for cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Neoadjuvant chemotherapy for operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Targeting the microtubules in breast cancer beyond taxanes: the epothilones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Progress and new standards of care in the management of HER-2 positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Angiogenesis as targeted breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Bisphosphonates in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

21 January 2018

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

7 January 2021

Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

7 January 2021

Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

7 January 2021

Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

7 January 2021

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

7 January 2021

Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

7 January 2021

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

7 January 2021

Benefit of taxanes as adjuvant chemotherapy for early breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

7 January 2021

Cardiac safety of liposomal anthracyclines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

7 January 2021

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

7 January 2021

Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

7 January 2021

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100449

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100449

1 reference

Dimensions Publication ID

17 August 2017

1039472682

0 references

1 reference